## BACHELOR OF PHARMACY (B. PHARM.) (CBCS - 2015 COURSE) Final Year B. Pharm. Sem-VII: WINTER: 2021 SUBJECT: BIOPHARMACEUTICS & PHARMACOKINETICS

Time: 02:00 PM-05:00 PM Day: Saturday Max. Marks: 60 **Date:** 15-01-2022 W-13722-2021 N.B. Q.No.1 and Q.No.5 are COMPULSORY. Out of the remaining questions 1) attempt ANY TWO questions from each section. 2) Figures to the right indicate **FULL** Marks. 3) Answers to the both sections should be written in **SEPARATE** answer books. **SECTION-I** Answer ANY FIVE of the following: **Q.1** (10)Classify drug transport mechanism. a) Phenobarbital and Salicylic and have almost the same  $K_{\text{o/w}}$  but the former shows extensive distribution. Why? Give the flow chart showing the different steps in biotransformation. c) A protein bound drug is pharmacokinetically and pharmacodynamically inert. Define total clearance and renal clearance and give its equations. e) f) Explain interfacial barrier theory of drug dissolution. Q.2 a) Describe in detail various patient related factors affecting drug absorption. (06)Give an account of physicochemical factors influencing drug distribution. (04)b) Explain the significance of protein drug binding. Q.3 a) (06)Explain the chemical factors affecting biotransformation. (04)**Q.4** Write a short note on **ANY TWO** of the following: (10)Factors affecting renal clearance a) Physiological barriers to drug distribution b) Salt from of drug c) **SECTION-II** Answer ANY FIVE of the following: Q.5 (10)Give examples of zero, first and mixed order process. a) What is meant by non-compartmental analysis? Give its advantages. b) Define bioavailability. What are the objectives of bioavailability studies? c) Name the methods used to calculate K<sub>E</sub> from urinary excretion data. d) What is the influence of  $K_a$  and  $K_E$  on  $C_{max}$ ,  $t_{max}$  and AUC. e) f) What are the advantages of urinary data over plasma data Derive the pharmacokinetic parameters following administration of IV bolus Q.6 a) (06)assuming one compartment open model. Discuss Wagner-Nelson method to obtain absorption rate constant K<sub>a</sub>. b) (04)Give detained account of bioequivalence experimental study design. Q.7 a) (06)Explain the pharmacokinetic based methods to determine bioavailability. b) (04)**Q.8** Write a short note on **ANY TWO** of the following: (10)Compartment modeling a) Methods to enhance bioavailability b) IVIVC c)